Abstract
Atherosclerosis is an inflammatory disease. The last three decades efforts have been made to elucidate the biochemical pathways that are implicated in the process of atherogenesis and plaque development. Chemokines are crucial mediators in every step of this process. Additionally, cellular components of the peripheral blood have been proved important mediators in the formation and progression of atherosclerotic lesions. However, until recently data were mostly focusing on leukocytes and platelets. Erythrocytes were considered unreceptive bystanders and limited data supported their importance in the progression and destabilization of the atherosclerotic plaque. Recently erythrocytes, through their Duffy antigen receptor for chemokines (DARC), have been proposed as appealing regulators of chemokine-induced pathways. Dissimilar to every other chemokine receptor DARC possesses high affinity for several ligands from both CC and CXC chemokine sub-families. Moreover, DARC is not coupled to a G-protein or any other intracellular signalling system; thus it is incapable of generating second messages. The exact biochemical role of erythrocyte DARC remains to be determined. It is however challenging the fact that DARC is a regulator of almost every CC and CXC chemokine ligand and therefore DARC antagonism could effectively block the complex pre-inflammatory chemokine network. In the present review we intent to provide recent evidence supporting the role of erythrocytes in atherosclerosis focusing on the erythrocyte-chemokine interaction through the Duffy antigen system.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Cutbush M, Mollison PL, The Duffy blood group system. Heredity 1950; 4: 383–9.
Lewis M, Kaita H, Chown B . The Duffy blood group in caucasians: A further population sample. Vox Sang 1972; 23: 523–7.
Pogo AO, Chaudhuri A . The Duffy protein: a malarial and chemokine receptor. Semin Hematol 2000; 37: 122–9.
Reich D, Nalls MA, Kao WH, Akylbekova EL, Tandon A, Patterson N, et al. Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. PLoS Genet 2009; 5: e1000360.
Pruenster M, Rot A . Throwing light on DARC. Biochem Soc Trans 2006; 34: 1005–8.
Meny GM . The Duffy blood group system: a review. Immunohematology 2010; 26: 51–6.
Hadley TJ, Peiper SC . From malaria to chemokine receptor: the emerging physiologic role of the Duffy blood group antigen. Blood 1997; 89: 3077–91.
Neote K, Malk JY, Kolakowski LF, Schall TJ . Functional and biochemical analysis of the cloned Duffy antigen: identity with the red blood cell chemokine receptor. Blood 1994; 84: 44–52.
Hellings WE, Peeters W, Moll FL, Pasterkamp G . From vulnerable plaque to vulnerable patient: the search for biomarkers of plaque destabilization. Trends Cardiovasc Med 2007; 17: 162–71.
Tziakas DN, Chalikias GK, Stakos D, Boudoulas H . The role of red blood cells in the progression and instability of atherosclerotic plaque. Int J Cardiol 2010; 142: 2–7.
Virmani R, Roberts WC . Extravasated erythrocytes, iron, and fibrin in atherosclerotic plaques of coronary arteries in fatal coronary heart disease and their relation to luminal thrombus: frequency and significance in 57 necropsy patients and in 2958 five mm segments of 224 major epicardial coronary arteries. Am Heart J 1983; 105: 788–97.
Arbustini E, Morbini P, D'Armini AM, Repetto A, Minzioni G, Piovella F, et al. Plaque composition in plexogenic and thromboembolic pulmonary hypertension: the critical role of the thrombotic material in pultaceous core formation. Heart 2002; 88: 177–82.
Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003; 349: 2316–25.
Minetti M, Agati L, Malorni W . An emerging concept in cardiovascular disease is the role of the erythrocyte as a “barometer” of overall cardiovascular health. The microenvironment can shift erythrocytes from a friendly to harmful behavior: pathogenic implications for vascular diseases. Cardiovasc Res 2007; 75: 21–8.
Yeagle PL . Cholesterol and the cell membrane. Biochim Biophys Acta 1985; 822: 267–87.
Yuan XM, Brunk UT, Olsson AG . Effects of iron- and hemoglobin-loaded human monocyte-derived macrophages on oxidation and uptake of LDL. Arterioscler Thromb Vasc Biol 1995; 15: 1345–51.
Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, et al. Atherosclerotic plaque progression and vulnerability to rupture: Angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005; 25: 2054–61.
Tziakas DN, Kaski JC, Chalikias GK, Romero C, Fredericks S, Tentes IK, et al. Total cholesterol content of erythrocyte membranes is increased in patients with acute coronary syndrome. J Am Coll Cardiol 2007; 49: 2081–9.
Tziakas DN, Chalikias GK, Stakos D, Tentes IK, Chatzikyriakou SV, Mitrousi K, et al. Cholesterol composition of erythrocyte membranes and its association with clinical presentation of coronary artery disease. Coron Artery Dis 2008; 19: 583–90.
Moreno P, Purushothaman KR, Sirol M, Levy AP, Fuster V . Neovascularization in human atherosclerosis. Circulation 2006; 113: 2245–52.
Neote K, Darbonne W, Ogez J, Horuk R, Schall TJ . Identification of a promiscuous inflammatory peptide receptor on the surface of red blood cells. J Biol Chem 1993; 268: 12247–9.
Darbonne WC, Rice GC, Mohler MA, Apple T, Hebert CA, Valente AJ, et al. Red blood cells are a sink for interleukin-8, a leukocyte chemotaxin. J Clin Invest 1991; 88: 1362–9.
Rubin O, Crettaz D, Tissot JD, Lion N . Microparticles in stored red blood cells: submicron clotting bombs? Blood Transfus 2010; 8: s31–s8.
Oreskovic RT, Dumaswala UJ, Greenwalt TJ . Expression of blood group antigens on red cell microvesicles. Transfusion 1992; 32: 848–9.
Xiong Z, Cavaretta J, Qu L, Stolz DB, Triulzi D, Lee JS . Red blood cell microparticles show altered inflammatory chemokine binding and release ligand upon interaction with platelets. Transfusion 2011; 51: 610–21.
Blum A . The possible role of red blood cell microvesicles in atherosclerosis. Eur J Intern Med 2009; 20: 101–5.
Luster AD . Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436–45.
Apostolakis S, Papadakis EG, Krambovitis E, Spandidos DA . Chemokines in vascular pathology (review). Int J Mol Med 2006; 17: 691–701.
Shimizu K, Mitchell RN . The role of chemokines in transplant graft arterial disease. Arterioscler Thromb Vasc Biol 2008; 28; 1937–49.
Jin T, Xu X, Hereld D . Chemotaxis, chemokine receptors and human disease. Cytokine 2008; 44: 1–8.
Comerford I, Nibbs RJ . Post-translational control of chemokines: a role for decoy receptors? Immunol Lett 2005; 96: 163–74.
Zernecke A, Shagdarsuren E, Weber C . Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 2008; 28: 1897–908.
Apostolakis S, Vogiatzi K, Amanatidou V, Spandidos DA . Interleukin 8 and cardiovascular disease. Cardiovasc Res 2009; 84: 353–60.
Weber C, Schober A, Zernecke A . Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 2004; 24: 1997–2008.
Barlic J, Murphy PM . Chemokine regulation of atherosclerosis. J Leukoc Biol 2007; 82: 226–36.
Weber KS, von Hundelshausen P, Clark-Lewis I, Weber PC, Weber C . Differential immobilization and hierarchical involvement of chemokines in monocyte arrest and transmigration on inflamed endothelium in shear flow. Eur J Immunol 1999; 29: 700–12.
Rus HG, Vlaicu R, Niculescu F . Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 1996; 127: 263–71.
Apostolopoulos J, Davenport P, Tipping PG . Interleukin-8 production by macrophages from atheromatous plaques. Arterioscler Thromb Vasc Biol 1996; 16: 1007–12.
Yue TL, Wang X, Sung CP, Olson B, McKenna PJ, Gu JL, et al. Interleukin-8. A mitogen and chemoattractant for vascular smooth muscle cells. Circ Res 1994; 75: 1–7.
Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA Jr, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999; 398: 718–23.
Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA . A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 1998; 101: 353–63.
Schwartz D, Andalibi A, Chaverri-Almada L, Berliner JA, Kirchgessner T, Fang ZT, et al. Role of the GRO family of chemokines in monocyte adhesion to MM-LDL-stimulated endothelium. J Clin Invest 1994; 94: 1968–73.
Huo Y, Weber C, Forlow SB, Sperandio M, Thatte J, Mack M, et al. The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J Clin Invest 2001; 108: 1307–14.
Mach F, Sauty A, Iarossi AS, Sukhova GK, Neote K, Libby P, et al. Differential expression of three T lymphocyteactivating CXC chemokines by human atheroma-associated cells. J Clin Invest 1999; 104: 1041–50.
Gear AR, Camerini D . Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation 2003; 10: 335–46.
Abi-Younes S, Sauty A, Mach F, Sukhova GK, Libby P, Luster AD . The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res 2000; 86: 131–8.
Schober A, Knarren S, Lietz M, Lin EA, Weber C . Crucial role of stromal cell-derived factor-1alpha in neointima formation after vascular injury in apolipoprotein E-deficient mice. Circulation 2003; 108: 2491–7.
Petersen F, Bock L, Flad HD, Brandt E . Platelet factor 4-induced neutrophil-endothelial cell interaction: involvement of mechanisms and functional consequences different from those elicited by interleukin-8. Blood 1999; 94: 4020–8.
Engstad CS, Lia K, Rekdal O, Olsen JO, Osterud B . A novel biological effect of platelet factor 4 (PF4): enhancement of LPS induced tissue factor activity in monocytes. J Leukoc Biol 1995; 58: 575–81.
Pitsilos S, Hunt J, Mohler ER, Prabhakar AM, Poncz M, Dawicki J, et al. Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost 2003; 90: 1112–20.
Yu G, Rux AH, Ma P, Bdeir K, Sachais BS . Endothelial expression of E-selectin is induced by the plateletspecific chemokine platelet factor 4 through LRP in an NF-kappaB dependent manner. Blood 2005; 105: 3545–51.
Nassar T, Sachais BS, Akkawi S, Kowalska MA, Bdeir K, Leitersdorf E, et al. Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J Biol Chem 2003; 278: 6187–93.
Rot A . Contribution of Duffy antigen to chemokine function. Cytokine Growth Factor Rev 2005; 16: 687–94.
Dawson TC, Lentsch AB, Wang Z, Cowhig JE, Rot A, Maeda N, et al. Exaggerated response to endotoxin in mice lacking the Duffy antigen/receptor for chemokines (DARC). Blood 2000; 96: 1681–4.
Nebor D, Durpes MC, Mougenel D, Mukisi-Mukaza M, Elion J, Hardy-Dessources MD, et al. Association between Duffy antigen receptor for chemokines expression and levels of inflammation markers in sickle cell anemia patients. Clin Immunol 2010; 136: 116–22.
Schnabel RB, Baumert J, Barbalic M, Dupuis J, Ellinor PT, Durda P, et al. Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators. Blood 2010; 115: 5289–99.
Lee JS, Frevert CW, Wurfel MM, Peiper SC, Wong VA, Ballman KK, et al. Duffy antigen facilitates movement of chemokine across the endothelium in vitro and promotes neutrophil transmigration in vitro and in vivo. J Immunol 2003; 170; 5244–51.
Mayr FB, Spiel AO, Leitner JM, Firbas C, Schnee J, Hilbert J, et al. Influence of the Duffy antigen on pharmacokinetics and pharmacodynamics of recombinant monocyte chemoattractant protein (MCP-1, CCL-2) in vivo. Int J Immunopathol Pharmacol 2009; 22: 615–25.
Pruenster M, Mudde L, Bombosi P, Dimitrova S, Zsak M, Middleton J, et al. The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity. Nat Immunol 2009; 10: 101–8.
de Winter RJ, Manten A, de Jong YP, Adams R, van Deventer SJ, Lie KI . Interleukin 8 released after acute myocardial infarction is mainly bound to erythrocytes. Heart 1997; 78: 598–602.
Lin HL, Xu XS, Lu HX, Zhang L, Li CJ, Tang MX, et al. Pathological mechanisms and dose dependency of erythrocyte-induced vulnerability of atherosclerotic plaques. J Mol Cell Cardiol 2007; 43: 272–80.
Tziakas DN, Chalikias GK, Tentes IK, Stakos D, Chatzikyriakou SV, Mitrousi K, et al. Interleukin-8 is increased in the membrane of circulating erythrocytes in patients with acute coronary syndrome. Eur Heart J 2008; 29: 2713–22.
Sluimer JC, Kolodgie FD, Bijnens AP, Maxfield K, Pacheco E, Kutys B, et al. Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions relevance of compromised structural integrity for intraplaque microvascular leakage. J Am Coll Cardiol 2009; 53: 1517–27.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Apostolakis, S., Chalikias, G., Tziakas, D. et al. Erythrocyte Duffy antigen receptor for chemokines (DARC): diagnostic and therapeutic implications in atherosclerotic cardiovascular disease. Acta Pharmacol Sin 32, 417–424 (2011). https://doi.org/10.1038/aps.2011.13
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2011.13
Keywords
This article is cited by
-
Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway
Acta Pharmacologica Sinica (2013)
